Fatty Liver Index (FLI)
Predicts hepatic steatosis (fatty liver) using BMI, waist circumference, triglycerides, and GGT. Validated as a non-invasive screening tool for NAFLD.
Score interpretation
FLI <30 — fatty liver ruled out with 87% accuracy
→ Low likelihood of steatosis; metabolic risk reduction counselling
FLI 30–59 — indeterminate result
→ Clinical assessment; consider liver ultrasound; address metabolic risk factors
FLI ≥60 — fatty liver present with ~85% accuracy
→ Lifestyle modification; weight loss target ≥10%; consider referral to hepatology; test for NASH/fibrosis (FIB-4, elastography)
Interpretation bands for the Fatty Liver Index. Apply clinical judgement and local guidance.
References
- Bedogni G et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
Related
Curated clinical cross-links plus same-class fallbacks.
- Omega-3-acid ethyl esters · Omega-3 fatty acids
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
- Hydroxycarbamide (Hydroxyurea) · Cytoreductive agent / Sickle cell disease / CML
- Acute Liver Failure · EASL 2017 / BSG
- Decompensated Cirrhosis · BSG 2015 / EASL 2018
- IBD Acute Flare Assessment · ECCO / BSG 2019
- Hepatitis B Management · EASL 2017 / NICE NG33
- Dysphagia Assessment Pathway · BSG 2010 / NICE NG12
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.